

Results of Wertheim-Meigs surgery for treatment of early uterine cervix cancer: An observational study

Karina Elord Castro Ribeiro da Silveira, Claudio Sergio Batista, Takasi Osako, Claudia Lucia Nunes Alvares

ABSTRACT

Aims: To verify Wertheim-Meigs surgery outcomes for treating early uterine cervix cancer. **Methods:** Observational, retrospective, not comparative study with cross-sectional data collection with 13 uterine cervical cancer patients stage IB to IIA undergoing to Wertheim-Meigs surgery from January 2000 to December 2012 in Petropolis, Rio de Janeiro, Brazil. **Main outcomes** were long disease-free, intraoperative and postoperative complications. **Included variables** were age, parity, sexual onset, number of partners, history of HPV infection, histological tumor type, status of surgical margins, lymph node involvement, and follow-up. **Data** were analyzed in PSPP software by calculating mean, median, and standard deviation. **Results:** Patients mean age was 43 ± 13.20 , parity 0.7 ± 0.82 kids and sexual partners 3.54 ± 3.55 . White women were 69.30%, black 7.69% and other races 15.68%. Sexual onset mean was 15.98 ± 5.75 . Squamous cell carcinoma was 69.23%, adenocarcinoma 7.69% and adenocarcinoma of endometrium 15.38%. Lymph node commitment was 1 case. Intraoperative complications were bladder injury 15.38%, and a case of ureter

section. Postoperative complications were intestine obstruction, cupola granuloma, and ureterovesical fistula a case each. Follow-up ranged from 1–7 years. **Conclusion:** Our study suggests despite of small sample it is need consider Wertheim-Meigs surgery as an efficient therapeutic option once the procedure presents good results and low complication rates.

Keywords: Cervix uteri, Gynecologic surgical procedures, Hysterectomy, Uterine cervical neoplasms

How to cite this article

da Silveira KECR, Batista CS, Osako T, Alvares CLN. Results of Wertheim-Meigs surgery for treatment of early uterine cervix cancer: An observational study. Edorium J Gynecol Obstet 2016;2:8–16.

Article ID: 100008G06KS2016

doi:10.5348/G06-2016-8-OA-2

Karina Elord Castro Ribeiro da Silveira¹, Claudio Sergio Batista², Takasi Osako³, Claudia Lucia Nunes Alvares³

Affiliations: ¹MD, Faculty of Medicine of Petrópolis, Rio de Janeiro, Brazil; ²MD, MSc, PhD, Adjunct Professor of Gynecology & Obstetrics of Faculty of Medicine of Petrópolis, Rio de Janeiro, Brazil; ³MD, UNIMED-Hospital, Petrópolis, Rio de Janeiro, Brazil.

Corresponding Author: Claudio Sergio Batista, Rua do Imperador, 288/908 – Centro – Petrópolis - Rio de Janeiro – Brazil – CEP: 25620-000; Email: csergiobatista@gmail.com

Received: 26 March 2016

Accepted: 17 May 2016

Published: 09 June 2016

INTRODUCTION

Uterine cervix cancer is the third kind of female cancer worldwide [1], and every year there are about 4,800 fatal casualties and presents around of 18,340 new cases [2, 3].

More than 85% of the global burden occurs in developing countries [4]

The main factor for uterine cervix cancer development is the human papillomavirus (HPV) infection, however, other factors may contribute for its carcinogenesis [5, 6].

Epidemiologically uterine cervix cancer is associated to early sexual onset, multiple sexual partners, low educational level, STD history, including chlamydial infection [7].

Initially, it is an oligosymptomatic or asymptomatic disease which leads many women to seek health service only when it is already in advanced stage, thereby reducing the chances of treatment and cure [8].

In disease evolving may arise episodes of nausea, vomiting, edema, lymphedema, intermittent vaginal bleeding, and after intercourse, vaginal secretions and abdominal pain, urinary and intestinal complaints at advanced cases [9].

The International Federation of Gynecology and Obstetrics establishes a standard staging for uterine cervix cancer (Table 1) whereas the stages IB and IIA as early, which can be treated by surgery or radiotherapy with high degree of success in both modes, while the stages of IIB to IV, advanced, have unfavorable prognosis [10].

According to Frederick, interest in developing surgical cure uterine cervix cancer predates the turn of 20th century, but despite these concerns, radical pelvic surgery showed excessive morbidity and mortality, thus the radiation treatment remained as choice for cervical cancer during the first half of 20th century, including reports of improvement in the survival of patients after the addition of pelvic lymphadenectomy to the radiation therapy [Taussig (1934, apud Frederick et al. 2011)], although some surgeons maintained the interest in improving surgical technique [11] as the inclusion of more extensive removal of parameters review and a complete pelvic lymphadenectomy proposed by Meigs [11, 12].

With regard to radical surgery complications, particularly fistulas, and its mortality these have been improved as the use of antibiotics and blood transfusions became more common [11].

In 1974, Piver et al., proposed a new classification for surgery for cervical cancer treatment in which establishes levels of surgical extension due to the different stages of the disease (Table 2), [11, 13] but classically uterine cervix cancer treatment has been divided into two groups, early stages (IA2, IB1, and small IIA with no parametrial involvement) and advanced stages (from IIB2 to IV) [14].

A new, simple and anatomy based classification of radical hysterectomy whose purpose was to preserve fertility, and, mainly, sympathetic and, parasympathetic innervation was described by Querleu and Morrow [15] and published in 2008, where they described four different types of surgery (Table 3).

This study evaluated Wertheim-Meigs surgery for early uterine cervix cancer. The aim of the study was to verify Wertheim-Meigs surgery outcomes for treating early uterine cervix cancer.

MATERIALS AND METHODS

We carried out a longitudinal, observational, retrospective, descriptive and not comparative study, with cross-sectional data collection on which were included 13 patients undergoing to Wertheim-Meigs

surgery for treating early uterine cervix cancer between 2000 to 2012 in Petropolis, a midsize highland city in the State of Rio de Janeiro, Brazil, as Public Health System, from Hospital Alcides Carneiro, as particular clinic from the surgeon that had performed the surgeries.

Included patients were from both the public health system, Alcides Castro Hospital, as the private clinic of the surgeon who performed the surgery.

It was included women whom had uterine cervix cancer stage IB to IIA by International Federation of Gynecology and Obstetrics (FIGO) 2009.

It were excluded women with uterine cervical cancer stage less than IB or greater than IIA, that received prior treatment by radiotherapy or chemotherapy, those with uterine cervix cancer concomitant to pregnancy, and those cases operated by other surgeons.

In this study, all patients were undergoing to surgical procedure by a unique surgeon in order to avoid the surgery execution bias, once it is a refined procedure and needs the same criteria of dissection in its execution, so all surgeries were performed by Wertheim-Meigs technic (Type III of Piver-Rutledge or Type C of Querleu-Morrow)

Assessed outcomes were intraoperative and postoperative complications and long-disease free.

Included variables were age, parity, sexual onset age, number of sexual partners, prior HPV infection history, histological tumor type, status of surgical margins, lymph node involvement and follow-up length.

Data were analyzed in PSPP software for statistical analysis (GNU PSPP version 0.8.2) by calculating mean, median and standard deviation.

This study is conformed to The Declaration of Helsinki and was approved by Faculty of Medicine of Petropolis Ethics Committee and registered under Certificate of Presentation for Ethical Consideration (CAAE – Certificado de Apresentação para Apreciação Ética) nº 24890614.6.0000.5245.

RESULTS

Patients age ranged 25–70 years (43±13.20), parity mean was of 0.7±0.82 kids/woman, mean of sexual partners was 3.54±3.55 per woman, white women were 9(69.30%), black was 1(7.69%) and other races were 3(15.68%), menarche ranged 10–17 years (12.92 ±1.71), sexual onset ranged 14–22 years (15.98±5.75), a patient reported never having had sexual intercourse and nobody mentioned neither HPV infection nor prior STD history.

Regarding to type of tumor we found 9 (69.23%) squamous cell carcinoma of uterine cervix, 2 (15.38%) adenocarcinoma of uterine cervix and 2 (15.38%) adenocarcinoma of endometrium.

About tumor stage 9 (69.23%) cases were IB and 2 (15.38%) were IA of uterine cervix cancer while other 2 (15.38%) were stage II A of endometrium carcinoma.

Ovaries were preserved in 6 (46.15%) cases, lymph

node and margins commitment occurred in 1 case and 2 cases, respectively.

Intraoperative complications were bowel injury in 2 (15.38%) cases and urether section, a case, and postoperative complications were intestine obstruction, cupola granuloma, and ureterovesical fistula a case each. Ureter section had evolution to ureteral stenosis. Follow-up length ranged from 1 to 7 years and had no death consequent to uterine cervix cancer among all cases. Results have been summarized in Tables 4 and 5.

DISCUSSION

This study shows the first results of an initial experience in surgical cervical cancer treatment from a gynecological surgery group in Petropolis, a midsize highland city of Rio de Janeiro, Brazil, whose goal is to promote medical care improvement in women who have uterine cervical cancer.

We Consider as strong point of our work, despite the small sample, the fact that all patients have been operated by a single surgeon, thus eliminating both the patient selection bias as to procedure, since it is a very specific surgery by its nuances and that surgery should only be performed by a surgeon with appropriate expertise after careful patients evaluation.

In other hand, we point as study limitation besides

sample size the absence of information of tumor extension in pathology analyses which did us perform Wertheim-Meigs surgery (Type III of Piver-Rutledge or Type C of Querleu-Morrow) in all cases even though knowing that one has more complications than type I and II surgery [14, 16].

In spite of new surgical techniques for treating early uterine cervix cancer in use such as laparoscopy and robotic surgery, we believe that it is important to remember radical surgery for this condition since many places do not have support for these new approaches, and more and more women are at risk for this cancer whose mortality is still high.

Factors influencing the decision to use surgery or definitive radiotherapy as the first treatment include patient factors (e.g., age, comorbidity, patient preference) and tumor factors (e.g., stage, tumor size, lymphovascular space invasion), as well as the physician's preference and resource availability [17], thus we just want bring the issue about treatment available at the time of cervical cancer diagnostic for discussion why maybe the Wertheim-Meigs surgery is the only one possible, but can be overlooked in name of most modern treatments but which are not available or feasible in certain regions such as ours.

According some authors, there is no standard management of stage Ib to IIa cervical carcinoma and most often, stage Ib1 cervical cancer is treated by radical hysterectomy with pelvic lymphadenectomy

Table 1: FIGO stages for uterine cervix cancer, 2009

Stage I	<p>Carcinoma is strictly confined to the cervix; extension to the uterine corpus should be disregarded. The diagnosis of both Stages IA1 and IA2 should be based on microscopic examination of removed tissue, preferably a cone, which must include the entire lesion</p> <p>IA: Invasive cancer identified only microscopically. Invasion is limited to measured stromal invasion with a maximum depth of 5 mm and no wider than 7 mm.</p> <p>IA1: Stage IA1: Measured invasion of the stroma no greater than 3 mm in depth and no wider than 7 mm diameter.</p> <p>IA2: Measured invasion of stroma greater than 3 mm but no greater than 5 mm in depth and no wider than 7 mm in diameter.</p> <p>IB: Clinical lesions confined to the cervix or preclinical lesions greater than Stage IA. All gross lesions even with superficial invasion are Stage IB cancers.</p> <p>IB1: Clinical lesions no greater than 4 cm in size.</p> <p>IB2: Clinical lesions greater than 4 cm in size.</p>
Stage II	<p>Carcinoma extends beyond the cervix, but does not extend into the pelvic wall. The carcinoma involves the vagina, but not as far as the lower third. Stage IIA: No obvious parametrial involvement. Involvement of up to the upper two-thirds of the vagina.</p> <p>Stage IIB: Obvious parametrial involvement, but not into the pelvic sidewall.</p>
Stage III	<p>Carcinoma has extended into the pelvic sidewall. On rectal examination, there is no cancer-free space between the tumour and the pelvic sidewall. The tumour involves the lower third of the vagina. All cases with hydronephrosis or a non-functioning kidney are Stage III cancers.</p> <p>IIIA: No extension into the pelvic sidewall but involvement of the lower third of the vagina.</p> <p>IIIB: Extension into the pelvic sidewall or hydronephrosis or non-functioning kidney.</p>
Stage IV	<p>Carcinoma has extended beyond the true pelvis or has clinically involved the mucosa of the bladder and/or rectum.</p> <p>IVA: Spread of the tumour into adjacent pelvic organs.</p> <p>IVB: Spread to distant organs.</p>

Source: TNM Classification of malignant tumours. L. Sobin and Ch Wittekind (eds.), UICC International Union against Cancer, Geneva, Switzerland. pp155-157; 6th ed. 2002. In: <http://screening.iarc.fr/viaviliappendix1.php?lang=1> <http://screening.iarc.fr/viaviliappendix1.php?lang=1> accessed on December 16, 2014.

* FIGO - International Federation of Gynecology and Obstetrics

Table 2: Piver, Rutledge and Smith types of hysterectomy: Simplified description.

Type 1	Hysterectomy is commonly referred to as the extrafascial, or simple, hysterectomy. This hysterectomy removes the cervix along with the uterine corpus, but does not require mobilization of the ureter or removal of a significant amount of the parametria.
Type 2	Modified radical hysterectomy, or Wertheim operation, requires more extensive dissection than the extrafascial hysterectomy. The central portion of the parametrial tissues is removed while minimizing disruption to the ureteral and vesical vasculature. Thus, the medial half of the uterosacral ligaments and the cardinal ligaments are removed as the uterine artery is ligated just medial to the point at which it crosses the ureter. Removal of a 1–2 cm portion of the upper vagina and pelvic and para-aortic lymphadenectomy are nearly always performed in conjunction with a type 2 radical hysterectomy.
Type 3	Radical hysterectomy, originally described by Meigs, aims to remove as much parametrial tissue as possible. The uterosacral ligaments are transected near their origin from the sacrum. The cardinal ligaments are excised as widely as possible after the uterine artery is ligated at its origin where it branches off the hypogastric artery. Care should be taken to preserve the superior vesical artery. Removal of a 2–3 cm portion of the upper vagina and a pelvic and para-aortic lymphadenectomy is performed in conjunction with a type 3 radical hysterectomy.
Type 4	Hysterectomy is seldom used, but represents an extended radical hysterectomy. It involves complete dissection of the ureter from the vesicouterine ligament, sacrifice of the superior vesical artery, and removal of up to 75% of the vagina.
Type 5	Hysterectomy also has limited applicability. This procedure involves resection of involved portions of the bladder or distal ureter with subsequent ureteral reimplantation. Occasionally, it substitutes for an anterior exenteration.

Source: Adapted from Frederick, P, Whitworth, J, et al. Glob. libr. women's med.,(ISSN: 1756-2228) 2011; DOI 10.3843/GLOWM.10232

Table 3: Classification of hysterectomy for invasive cervix cancer according to Querleu and Morrow in 2008

Type A Extrafascial hysterectomy - Minimum resection of paracervix (corresponds to the type I RH)	Lateral parametrium removed to the ureter Ureter not tunneled Anterior and posterior parametrium not removed Vessels removed maximally close to the uterus Vaginal resection is minimal without removal of the paracolpos
Type B Transection of paracervix at the ureter (corresponds to the type II RH)	Ureter tunneled Partial resection of utero-sacral and vesico-uterine ligaments Resection of para-cervical ligament at the level of ureteral tunnel
Type C Transection of paracervix at junction with internal iliac vascular system (corresponds to type III RH)	Transection of lateral parametrium to the iliac vessels Transection of vesico-uterine ligament at the bladder Transection of utero-sacral ligament at the rectum Ureter completely mobilized
Type C1 With autonomic nerve sparing/preservation	Lateral parametrium – preservation of splanchnic nerves Ventral parametrium – preservation of vesical branch of pelvic plexus Dorsal parametrium – preservation of hypogastric nerve
Type C2 Without autonomic nerve sparing/preservation	Lateral parametrium - intersection of the splanchnic nerve Ventral parametrium – intersection of vesical branch of pelvic plexus Dorsal parametrium – all branches of hypogastric nerve are dissected
Type D Lateral parametrectomy:	The line of resection runs between internal obturator internus muscle and lumbosacral plexus

Source: Adapted from Querleu D, Morrow CP. Classification of radical hysterectomy. Lancet Oncol 2008;9(3):297-303.

[18]. However it has been showed that extra-fascial hysterectomy is generally considered adequate treatment for stage Ia1 cervical cancer type 2 modified radical hysterectomy with pelvic lymphadenectomy is usually used for stage Ia2 cervical cancer [11, 19] and type

3 radical hysterectomy with pelvic and para-aortic lymphadenectomy is used for patients with stage Ib and IIa cervical cancer [11].

Many gynecologic oncologists are in favor non-operative treatment in elderly patients and 65 years

Table 4: Baseline patient undergoing to Wertheim-Meigs surgery characteristics

Variable	n (%)	Mean ± DP	Median
Age (years)		43±13.20	43
25–40	06 (46.15)		
41–50	05 (38.46)		
51–70	02 (15.38)		
Parity		0,7±0.82	1
none	05 (38.46)		
1	03 (23.07)		
2	02 (15.38)		
3 or more	03 (23.07)		
Number of sexual partners		3.54±3.55	3
1	02 (15.38)		
2	03 (23.07)		
3	03 (23.07)		
4 ou mais	05 (38.46)		
Race			
White	09 (69.23)		
Black	4 (30.76)		
Menarch (years)		12.92±1.71	13
10–14	11(84.61)		
15–17	02(15.38)		
Sexual onset (years)		15,98±5,75	17
14–17	7(53.38)		
18–22	5(38.46)		
Not referred	1 (7.69)		
Prior STD			
Yes	0		
No	13 (100.0)		
Prior HPV			
Yes	3 (23.07)		
No	10 (76.92)		

Table 5: Tumoral characteristics of patients undergoing to Wertheim-Meigs surgery

Characteristics	n (%)
Histological type	
Squamous Cell Carcinoma	09 (69.23)
Adenocarcinoma of uterine cervix	2 (15.38%)
Adenocarcinoma of Endometrium	02 (15.38)
Stage	
IA	02 (15.38)
IIA	02 (15.38)
IB	09 (69.23)
Ovary preservation	
Yes	6 (46.15)
No	7 (53.84)
Lymph node involvement	
Yes	01 (7.69)
No	09 (69.23)
Not informed	03 (23.07)
Surgical margins commitment	
Yes	2 (15.38)
No	11 (84.61)
Intraoperative complications	
Yes	03 (23.07)
Bowel injury	02 (15.38)
Urether section	01 (7.69)
No	10 (76.92)
Postoperative complications	
Yes	03 (23.07)
Stenosis of ureter	01 (7.69)
Intestinal obstruction	01 (7.69)
Granuloma of vaginal cuppola	01 (7.69)
No	10 (76.92)
Follow up (months)	
12–35	07 (53.84)
36–48	01 (7.69)
60–72	01 (7.69)
72 or more	01 (7.69)
Not informed	03 (23.07)

of age is frequently cited as the limit for consideration of radical hysterectomy. However, other authors have found that the morbidity and survival of older patients is comparable with that of younger patients [20, 21].

It was included in this series a 70-year-old patient and it was observed similar evolution to that of younger patients. Intraoperative and postoperative complication rates are 4% and 12%, respectively.

Ten percent of patients had indications for adjuvant treatments. The risk of recurrence is statistically higher for those with tumor sizes >2 cm and LVSI [22] Intraoperatively, the most common complication of radical hysterectomy is hemorrhage; the range of reported average blood loss is from 600 mL to 1900 mL [23–25] but in this study there was no significant bleeding or need of blood transfusion.

Complications that arise during the postoperative period include both early and late complications. Early complications are those occurring within the first 30 postoperative days, may vary [11].

It has been reported that up to 40% of early cervical cancers are diagnosed in young women [26] and our study showed 46.15% of cases ranging from 25 to 40 years.

In this study, all cases were uterine cervix cancer stage IB and adenocarcinoma of endometrium stage IIA in according to literature which establish two treatment options such as primary surgery or chemo-radiotherapy depending on the individual characteristics, comorbidities and preferences [18, 27].

Although most uterine cervix cancer are squamous cell carcinomas, the incidence of such carcinomas has declined over time, and cervical adenocarcinoma has risen in recent years, and human papillomavirus (HPV) infection and others cofactors may explain this differential trend is unclear [28] and although our results showed prevalence of squamous cell carcinoma we had no evidence of HPV infection neither on cancer diagnosis nor as prior STD infection.

Regarding to lymph nodes spread this is common and usually occurs in a stepwise fashion, first to pelvic lymph nodes and then to para-aortic nodes. It is estimated that 15% of stage I, 30% of stage II, and 45% of stage III patients have pelvic nodal disease [22, 29].

We had only 01(7.69%) pelvic lymph nodes commitment.

Complications in radical surgery seen in our work are in according to what has been showed in literature [11] and are at acceptable levels however we do not are able to affirm the range of complications would be the same if we had had more cases.

CONCLUSION

Despite our small sample and although there are new procedures for treatment of early uterine cervical cancer it is necessary to consider the surgery of Wertheim-Meigs

as efficient therapeutic option and our study suggests it provides good results and an acceptable complications rates.

Author Contributions

Karina Elord Castro Ribeiro da Silveira – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Final approval of the version to be published

Claudio Sergio Batista – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Takasi Osako – Acquisition of data, Revising it critically for important intellectual content, Final approval of the version to be published

Claudia Lucia Nunes Alvares – Acquisition of data, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor

The corresponding author is the guarantor of submission.

Conflict of Interest

Authors declare no conflict of interest.

Copyright

© 2016 Karina Elord Castro Ribeiro da Silveira et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. [Available at: <http://globocan.iarc.fr>]
2. Anttila A, von Karsa L, Aasmaa A, et al. Cervical cancer screening policies and coverage in Europe. *Eur J Cancer* 2009 Oct;45(15):2649–58.
3. Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. *Eur J Cancer* 2009 Oct;45(15):2640–8.
4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011 Mar-Apr;61(2):69–90.
5. Nakagawa JT, Schirmer J, Barbieri M. Human Papillomavirus (HPV) and uterine cervical cancer.

- [Article in Portuguese]. *Rev Bras Enferm* 2010 Mar-Apr;63(2):307–11.
6. Murta EFC, Souza MAH, Lombardi W, Borges LS. Aspectos epidemiológicos da infecção pelo papilomavírus humano. *J bras ginecol* 1997;107(4):95–9.
 7. Pinto AP, Tulio S, Cruz OR. Hpv cofactors in cervical carcinogenesis. [Article in Portuguese]. *Rev Assoc Med Bras* 2002 Jan-Mar;48(1):73–8.
 8. Pimentel AV, Panobianco MS, Almeida AM, Oliveira ISB. A percepção da vulnerabilidade entre mulheres com diagnóstico avançado do câncer do colo do útero. *Texto Contexto Enferm* 2011 Abr-Jun;20(2):255–62.
 9. INCa (Instituto Nacional do Câncer). Estimativa 2012- Incidência de Câncer no Brasil. [Disponível em: <http://www.inca.gov.br/estimativa/2012/estimativa20122111.pdf>]
 10. Pecorelli S. Revised FIGO staging of carcinoma of the vulva, cervix, and endometrium. *International J of Gynecol and Obstet* 2009;105(2):103–4.
 11. Frederick, P, Whitworth, J, Alvarez R. Radical hysterectomy for carcinoma of the uterine cervix. *The Global Library of Women's Medicine and Healthcare* 2011.
 12. Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer. *Obstet Gynecol* 1974 Aug;44(2):265–72.
 13. Cannistra SA, Niloff JM. Cancer of the uterine cervix. *N Engl J Med* 1996 Apr 18;334(16):1030–8.
 14. Trimpos JB, Franchi M, Zanaboni F, Velden Jv, Vergote I. 'State of the art' of radical hysterectomy; current practice in European oncology centres. *Eur J Cancer* 2004 Feb;40(3):375–8.
 15. Querleu D, Morrow CP. Classification of radical hysterectomy. *Lancet Oncol* 2008 Mar;9(3):297–303.
 16. Covens A, Rosen B, Murphy J, et al. Changes in the demographics and perioperative care of stage IA(2)/IB(1) cervical cancer over the past 16 years. *Gynecol Oncol* 2001 May;81(2):133–7.
 17. Hall EJ, Wu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. *Int J Radiat Oncol Biol Phys* 2003 May 1;56(1):83–8.
 18. Kesic V. Management of cervical cancer. *Eur J Surg Oncol* 2006 Oct;32(8):832–7.
 19. Hacker NF. Cervical cancer. In: Berek JS, Hacker NF eds. *Practical gynecologic oncology*, 3ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 345–405.
 20. Geisler JP, Geisler HE. Radical hysterectomy in the elderly female: a comparison to patients age 50 or younger. *Gynecol Oncol* 2001 Feb;80(2):258–61.
 21. Mousavi A, Karimi Zarchi M, Gilani MM, et al. Radical hysterectomy in the elderly. *World J Surg Oncol* 2008 Apr 7;6:38.
 22. Barbera L, Thomas G. Management of early and locally advanced cervical cancer. *Semin Oncol* 2009 Apr;36(2):155–69.
 23. Lerner HM, Jones HW 3rd, Hill EC. Radical surgery for the treatment of early invasive cervical carcinoma (stage IB): review of 15 years' experience. *Obstet Gynecol* 1980 Oct;56(4):413–8.
 24. Samlal RAK, Velden JVD, Ketting BW, et al. Disease-free interval and recurrence pattern after the Okabayashi variant of Wertheim's radical hysterectomy for stage IB and IIA cervical carcinoma. *International Journal of Gynecological Cancer* 1996;6:120–7.
 25. Benjamin I, Barakat RR, Curtin JP, Jones WB, Lewis JL Jr, Hoskins WJ. Blood transfusion for radical hysterectomy before and after the discovery of transfusion-related human immunodeficiency virus infection. *Obstet Gynecol* 1994 Dec;84(6):974–8.
 26. Plante M. Evolution in fertility-preserving options for early-stage cervical cancer: radical trachelectomy, simple trachelectomy, neoadjuvant chemotherapy. *Int J Gynecol Cancer* 2013 Jul;23(6):982–9.
 27. Kyrgiou M, Shafi MI. Invasive cancer of the cervix. *Obstetrics, Gynaecology And Reproductive Medicine* 2013;23(11):343–51.
 28. Castellsagué X, Díaz M, de Sanjosé S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. *J Natl Cancer Inst* 2006 Mar 1;98(5):303–15.
 29. Vinh-Hung V, Bourgain C, Vlastos G, et al. Prognostic value of histopathology and trends in cervical cancer: a SEER population study. *BMC Cancer* 2007 Aug 23;7:164.

Access full text article on
other devices



Access PDF of article on
other devices

